{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:51:40Z","timestamp":1790639500944,"version":"4.1.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"crossref","award":["Biomedical Grant"],"award-info":[{"award-number":["Biomedical Grant"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["Grant"],"award-info":[{"award-number":["Grant"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00109-020-02030-6","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T21:02:36Z","timestamp":1609707756000},"page":"311-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America"],"prefix":"10.1007","volume":"99","author":[{"given":"Alexandre P.","family":"Garneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Haydock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence E.","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5569-6258","authenticated-orcid":false,"given":"Paul","family":"Isenring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"2030_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41574-019-0180-z","volume":"15","author":"F Brioude","year":"2019","unstructured":"Brioude F, Toutain A, Giabicani E, Cottereau E, Cormier Daire V, Netchine I (2019) Overgrowth syndromes \u2013 clinical and molecular aspects and tumour risk. Nat Rev Endocrinol 15:299\u2013311","journal-title":"Nat Rev Endocrinol"},{"key":"2030_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","volume":"558","author":"Q Venot","year":"2018","unstructured":"Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC, Hoguin C, Boccara O, Sarnacki S, Boddaert N, Pannier S, Martinez F, Magassa S, Yamaguchi J, Knebelmann B, Merville P, Grenier N, Joly D, Cormier-Daire V, Michot C, Bole-Feysot C, Picard A, Soupre V, Lyonnet S, Sadoine J, Slimani L, Chaussain C, Laroche-Raynaud C, Guibaud L, Broissand C, Amiel J, Legendre C, Terzi F, Canaud G (2018) Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 558:540\u2013546","journal-title":"Nature"},{"key":"2030_CR3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929\u20131940","journal-title":"N Engl J Med"},{"key":"2030_CR4","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/humu.22431","volume":"34","author":"N Revencu","year":"2013","unstructured":"Revencu N, Boon LM, Mendola A, Cordisco MR, Dubois J, Clapuyt P, Hammer F, Amor DJ, Irvine AD, Baselga E et al (2013) RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation. Hum Mutat 34:1632\u20131641","journal-title":"Hum Mutat"},{"key":"2030_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1056\/NEJMoa1709449","volume":"378","author":"SI Nikolaev","year":"2018","unstructured":"Nikolaev SI, Vetiska S, Bonilla X, Boudreau E, Jauhiainen S, Rezai Jahromi B, Khyzha N, DiStefano PV, Suutarinen S, Kiehl TR et al (2018) Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med 378:250\u2013261","journal-title":"N Engl J Med"},{"key":"2030_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","volume":"154","author":"MK Koenig","year":"2018","unstructured":"Koenig MK, Bell CS, Hebert AA, Roberson J, Samuels JA, Slopis JM, Tate P, Northrup H, for the TREATMENT Trial Collaborators (2018) Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial. JAMA Dermatol 154:773\u2013780","journal-title":"JAMA Dermatol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-02030-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-020-02030-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-02030-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T13:23:41Z","timestamp":1614000221000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-020-02030-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["2030"],"URL":"https:\/\/doi.org\/10.1007\/s00109-020-02030-6","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval has been obtained by the CHU de Qu\u00e9bec. Signed agreement to participate has also been obtained by the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Signed agreement to participate has been obtained by the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and for publication"}}]}}